STAT

Discovery of unknown lung cell points to new target for cystic fibrosis medicines

The discovery could shift the understanding of the basic biology of cystic fibrosis, provide potential new targets for therapies, and one day shake up the market for CF medications.

The researchers set out to take a census of all the cells that line our airway, a taxonomy of the tissue made possible by new technology. Perhaps, they thought, they would find different subtypes of cells they already knew existed or would come to better understand the cells’ functions.

As the data came in, though, they pointed to a more intriguing finding: a previously unknown cell, one that was similar to a cell found in the gills of fish and skin of frogs.

Senior researchers were initially dubious. “I thought, ‘It’s great to have graduate students who are so bold,’ but in the back of my head, I was thinking there was no way this was right,” said Dr. Jay

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks